Sugi Predict

Sugi Predict / Compounds / SCHEMBL1496112

SCHEMBL1496112

SCHEMBL1496112

NC(=O)c1nnc(Nc2ccccn2)c2cc(-c3cccc(Cl)c3)sc12

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 4/20 0.49
▸ JAK3 P52333 1/20 0.49
▸ CHEK1 O14757 5/20 0.47
▸ IKBKB O14920 1/20 0.43
▸ CNR2 P34972 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ KDR P35968 1/20 0.39
▸ FLT1 P17948 1/20 0.39
▸ NUDT1 P36639 1/20 0.37
▸ BTK Q06187 1/20 0.37
▸ CYP1A1 P04798 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP1B1 Q16678 1/20 0.37
▸ TLR7 Q9NYK1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496042 0.92 CHEK1 (0.55) JAK2JAK3CHEK1IKBKBKDR
SCHEMBL1496162 0.84 CHEK1 (0.49) JAK2CHEK1IKBKBALDH1A1KDR
SCHEMBL1496118 0.82 JAK2 (0.49) JAK2JAK3CHEK1IKBKBALDH1A1
SCHEMBL1496131 0.82 CHEK1 (0.50) JAK2CHEK1IKBKBKDRFLT1
SCHEMBL1496018 0.81 CHEK1 (0.47) JAK2CHEK1IKBKBALDH1A1KDR
SCHEMBL1496079 0.80 CHEK1 (0.49) JAK2CHEK1IKBKBALDH1A1KDR
SCHEMBL1496085 0.80 CHEK1 (0.49) JAK2CHEK1IKBKBALDH1A1KDR
SCHEMBL1496167 0.78 CHEK1 (0.45) JAK2CHEK1IKBKBKDRFLT1
SCHEMBL1496109 0.78 JAK2 (0.45) JAK2JAK3CHEK1IKBKBALDH1A1
SCHEMBL1496147 0.75 CHEK1 (0.58) JAK2CHEK1IKBKBKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2024-01-11 — — US claimed
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2023-02-16 — — US claimed
CN-115038439-A Combination cancer therapy with CHK inhibitors 上海华禹生物科技有限公司 2022-09-09 — — CN claimed
CN-115038440-A Combination cancer therapy with CHK inhibitors 上海华禹生物科技有限公司 2022-09-09 — — CN claimed
US-20150072987-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION SHANGHAI HUAYU BIOTECH CO., LTD (CN) 2015-03-12 — — US claimed
US-8815863-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2014-08-26 — — US claimed
US-20120232082-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2012-09-13 — — US claimed
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2024-01-11 — — US disclosed
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2023-02-16 — — US disclosed
CN-115038439-A Combination cancer therapy with CHK inhibitors 上海华禹生物科技有限公司 2022-09-09 — — CN disclosed
CN-115038440-A Combination cancer therapy with CHK inhibitors 上海华禹生物科技有限公司 2022-09-09 — — CN disclosed
WO-2021141974-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR WU FAN (US) 2021-07-15 — — WO disclosed
US-9487539-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD (CN) 2016-11-08 — — US disclosed
US-20150072987-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION SHANGHAI HUAYU BIOTECH CO., LTD (CN) 2015-03-12 — — US disclosed
EP-2826780-A1 Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition Wu, Zhanggui (US) 2015-01-21 — — EP disclosed
US-8815863-B2 Compounds and therapeutic use thereof for protein kinase inhibition SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2014-08-26 — — US disclosed
EP-2477496-B1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION WU ZHANGGUI (US) 2014-04-16 — — EP disclosed
US-20120232082-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION SHANGHAI HUAYU BIOTECH CO., LTD. (CN) 2012-09-13 — — US disclosed
EP-2477496-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION Wu, Zhanggui (US) 2012-07-25 — — EP disclosed
WO-2011035077-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION WU ZHANGGUI (US) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR CHEK1, DCK, CHEK2 JAK2 1341/4885JAK3 1409/4885CHEK1 1/4885
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR CHEK1, CHEK2, DCK JAK2 1101/4885JAK3 1182/4885CHEK1 1/4885
US-20150072987-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION CHEK2, CHEK1, PLK1 JAK2 839/4885JAK3 1174/4885CHEK1 2/4885
US-20120232082-A1 NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION CHEK2, CHEK1, BUB1B JAK2 811/4885JAK3 1095/4885CHEK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.